Pages that link to "Q117252310"
Jump to navigation
Jump to search
The following pages link to Marie Odile Petillon (Q117252310):
Displaying 8 items.
- Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results (Q39062058) (← links)
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (Q39485433) (← links)
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (Q42914716) (← links)
- Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial (Q42940540) (← links)
- IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. (Q44818652) (← links)
- Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. (Q48250873) (← links)
- Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial (Q91750643) (← links)
- Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial (Q92892510) (← links)